Comparative Pharmacology
Head-to-head clinical analysis: AUVELITY versus SERZONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUVELITY versus SERZONE.
AUVELITY vs SERZONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AUVELITY (dextromethorphan HBr and bupropion HCl) is an NMDA receptor antagonist (via dextromethorphan) and a norepinephrine-dopamine reuptake inhibitor (via bupropion). Dextromethorphan also modulates sigma-1 receptor activity.
Serzone (nefazodone) is a serotonin antagonist and reuptake inhibitor (SARI). It blocks postsynaptic 5-HT2 receptors and inhibits serotonin and norepinephrine reuptake, leading to increased serotonergic and noradrenergic neurotransmission.
45 mg orally once daily, given as dextromethorphan hydrobromide 45 mg and bupropion hydrochloride 105 mg combination tablet.
Initial 100 mg orally twice daily; titrate to 200-300 mg twice daily. Maximum 600 mg/day.
None Documented
None Documented
Dextromethorphan: 13.5 hours (terminal half-life; prolonged due to CYP2D6 inhibition by bupropion, allowing sustained NMDA antagonism; bupropion: 13.7 hours)
Terminal elimination half-life is 18-22 hours for nefazodone; steady-state achieved in 3-5 days.
Renal 81% (dextromethorphan and metabolites: 78% as unchanged drug and 3% as dextrorphan conjugates), fecal 9% (dextromethorphan and metabolites), biliary <1%
Primarily hepatic metabolism; <1% excreted unchanged renally; metabolites excreted in urine (approximately 85%) and feces (approximately 15%).
Category C
Category C
Antidepressant
Antidepressant